MK-0626 (MK-626) is a potent, selective and orally active DPP-4 inhibitor (IC50=6.3 nM) with excellent selectivity.
MK-0626 attenuates hepatic steatosis through enhancing AMPK activity, inhibiting hepatic lipogenic gene expression, enhancing triglyceride secretion from liver and increasing serum adiponectin levels in ob/ob mice.
MK-0626 significantly increased the mRNA expression of PPARα and microsomal triglyceride transfer protein but significantly reduced sterol regulatory element binding transcription factor-1c, fatty acid synthase and stearoyl-CoA desaturase-1.
